Rheopheresis for age-related macular degeneration: Clinical results and putative mechanism of action

Jose S Pulido, Donald Sanders, Reinhard Klingel

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background: Rheopheresis is being evaluated in a clinical trial. The rationale and available results are presented. Methods: We reviewed the literature about the pathophysiology of age-related macular degeneration (AMD) that might support the use of rheopheresis. In addition, we reviewed the previously published results of the use of rheopheresis for AMD. Results: There appears to be a diffusion barrier caused by accumulation of cross-linked proteins known as advanced macular oxidation products (AMOPS) in AMD. Rheopheresis allows removal of uncross-linked proteins and facilitates antioxidant entry into Bruch's membrane, preventing further accumulation of AMOPS. The Multicenter Investigation of Rheopheresis for AMD (MIRA-1), an ongoing double-masked randomized trial, should determine the efficacy of rheopheresis in preventing the progression of AMD. The interim results, from an analysis of visual acuity data for 43 patients, are encouraging, confirming the potential of rheopheresis as a therapeutic option for dry AMD. The benefit was evident immediately after treatment and remained essentially stable throughout the 12-month period of evaluation. Eyes with late-stage, high-risk, dry AMD appeared to be at significant risk for substantial vision loss over the 12 months if not treated. Subgroup analysis demonstrated that the timing of rheopheresis in the course of a patient's disease may have a pronounced effect on outcome. Interpretation: There appears to be a rationale for the use of rheopheresis in AMD. Further results of the clinical trial are awaited.

Original languageEnglish (US)
Pages (from-to)332-340
Number of pages9
JournalCanadian Journal of Ophthalmology
Volume40
Issue number3
StatePublished - 2005

Fingerprint

Macular Degeneration
Clinical Trials
Bruch Membrane
Visual Acuity
Proteins
Antioxidants
Therapeutics

Keywords

  • Age factor
  • Macular degeneration
  • Rheopheresis

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Rheopheresis for age-related macular degeneration : Clinical results and putative mechanism of action. / Pulido, Jose S; Sanders, Donald; Klingel, Reinhard.

In: Canadian Journal of Ophthalmology, Vol. 40, No. 3, 2005, p. 332-340.

Research output: Contribution to journalArticle

@article{ce92abad7c3f4e9a83e7049a575e7543,
title = "Rheopheresis for age-related macular degeneration: Clinical results and putative mechanism of action",
abstract = "Background: Rheopheresis is being evaluated in a clinical trial. The rationale and available results are presented. Methods: We reviewed the literature about the pathophysiology of age-related macular degeneration (AMD) that might support the use of rheopheresis. In addition, we reviewed the previously published results of the use of rheopheresis for AMD. Results: There appears to be a diffusion barrier caused by accumulation of cross-linked proteins known as advanced macular oxidation products (AMOPS) in AMD. Rheopheresis allows removal of uncross-linked proteins and facilitates antioxidant entry into Bruch's membrane, preventing further accumulation of AMOPS. The Multicenter Investigation of Rheopheresis for AMD (MIRA-1), an ongoing double-masked randomized trial, should determine the efficacy of rheopheresis in preventing the progression of AMD. The interim results, from an analysis of visual acuity data for 43 patients, are encouraging, confirming the potential of rheopheresis as a therapeutic option for dry AMD. The benefit was evident immediately after treatment and remained essentially stable throughout the 12-month period of evaluation. Eyes with late-stage, high-risk, dry AMD appeared to be at significant risk for substantial vision loss over the 12 months if not treated. Subgroup analysis demonstrated that the timing of rheopheresis in the course of a patient's disease may have a pronounced effect on outcome. Interpretation: There appears to be a rationale for the use of rheopheresis in AMD. Further results of the clinical trial are awaited.",
keywords = "Age factor, Macular degeneration, Rheopheresis",
author = "Pulido, {Jose S} and Donald Sanders and Reinhard Klingel",
year = "2005",
language = "English (US)",
volume = "40",
pages = "332--340",
journal = "Canadian Journal of Ophthalmology",
issn = "0008-4182",
publisher = "Canadian Ophthalmological Society",
number = "3",

}

TY - JOUR

T1 - Rheopheresis for age-related macular degeneration

T2 - Clinical results and putative mechanism of action

AU - Pulido, Jose S

AU - Sanders, Donald

AU - Klingel, Reinhard

PY - 2005

Y1 - 2005

N2 - Background: Rheopheresis is being evaluated in a clinical trial. The rationale and available results are presented. Methods: We reviewed the literature about the pathophysiology of age-related macular degeneration (AMD) that might support the use of rheopheresis. In addition, we reviewed the previously published results of the use of rheopheresis for AMD. Results: There appears to be a diffusion barrier caused by accumulation of cross-linked proteins known as advanced macular oxidation products (AMOPS) in AMD. Rheopheresis allows removal of uncross-linked proteins and facilitates antioxidant entry into Bruch's membrane, preventing further accumulation of AMOPS. The Multicenter Investigation of Rheopheresis for AMD (MIRA-1), an ongoing double-masked randomized trial, should determine the efficacy of rheopheresis in preventing the progression of AMD. The interim results, from an analysis of visual acuity data for 43 patients, are encouraging, confirming the potential of rheopheresis as a therapeutic option for dry AMD. The benefit was evident immediately after treatment and remained essentially stable throughout the 12-month period of evaluation. Eyes with late-stage, high-risk, dry AMD appeared to be at significant risk for substantial vision loss over the 12 months if not treated. Subgroup analysis demonstrated that the timing of rheopheresis in the course of a patient's disease may have a pronounced effect on outcome. Interpretation: There appears to be a rationale for the use of rheopheresis in AMD. Further results of the clinical trial are awaited.

AB - Background: Rheopheresis is being evaluated in a clinical trial. The rationale and available results are presented. Methods: We reviewed the literature about the pathophysiology of age-related macular degeneration (AMD) that might support the use of rheopheresis. In addition, we reviewed the previously published results of the use of rheopheresis for AMD. Results: There appears to be a diffusion barrier caused by accumulation of cross-linked proteins known as advanced macular oxidation products (AMOPS) in AMD. Rheopheresis allows removal of uncross-linked proteins and facilitates antioxidant entry into Bruch's membrane, preventing further accumulation of AMOPS. The Multicenter Investigation of Rheopheresis for AMD (MIRA-1), an ongoing double-masked randomized trial, should determine the efficacy of rheopheresis in preventing the progression of AMD. The interim results, from an analysis of visual acuity data for 43 patients, are encouraging, confirming the potential of rheopheresis as a therapeutic option for dry AMD. The benefit was evident immediately after treatment and remained essentially stable throughout the 12-month period of evaluation. Eyes with late-stage, high-risk, dry AMD appeared to be at significant risk for substantial vision loss over the 12 months if not treated. Subgroup analysis demonstrated that the timing of rheopheresis in the course of a patient's disease may have a pronounced effect on outcome. Interpretation: There appears to be a rationale for the use of rheopheresis in AMD. Further results of the clinical trial are awaited.

KW - Age factor

KW - Macular degeneration

KW - Rheopheresis

UR - http://www.scopus.com/inward/record.url?scp=21744436076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21744436076&partnerID=8YFLogxK

M3 - Article

C2 - 15947803

AN - SCOPUS:21744436076

VL - 40

SP - 332

EP - 340

JO - Canadian Journal of Ophthalmology

JF - Canadian Journal of Ophthalmology

SN - 0008-4182

IS - 3

ER -